AstraZeneca
阿斯利康
AstraZeneca is a global pharmaceutical company actively expanding into next-generation cell and gene therapies. In March 2025, it acquired Belgian biotech EsoBiotec for $1 billion to advance in vivo CAR-T approaches, per a Gaorong Future report . The company has also built a partnership footprint in China's biotech ecosystem: it took an equity stake in Syneron Bio as part of a strategic collaboration announced in March 2025 to co-develop first-in-class macrocyclic peptide drugs for chronic diseases, with deal terms including a $75 million upfront and up to $3.4 billion in milestones , and participated in the same firm's $150 million Series B in March 2026 . Earlier, in early 2023, it partnered with WeDoctor to facilitate mainland Chinese patients booking Evusheld antibody injections in Hong Kong .
AI-generated — may contain errors, please verify.
Coverage
5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
Westlake Valley Intelligent Pharma: Cracking the AAV Delivery Challenge with AI, Entering the Super Track of In Vivo CAR-T — Gene Therapy's Moment in China | Gaorong Future
Chinese gene therapies have a real shot at genuine innovation — even leapfrogging the competition.
April: Curiosity and New Paths | 5Y News Monthly
The big news from last month.
5Y News｜Syneron Bio Enters Strategic Partnership with AstraZeneca
Continue to track technological innovation in the biopharma space.
Interview with RayzeBio: Two Funding Rounds in Six Months, How the Surging "Radiopharma" Sector Is Transforming Cancer Treatment | Gaorong Ventures
Accelerating on the "fast track" of TRT therapy.
2025: Three Directions Where AI Is Reshaping Drug Discovery
How Can AI Help Drug Development Cross the "Valley of Death"?
OpenAI Releases GPT-4o mini: Faster and Cheaper
Speed is justice.
Inside Dalton Venture's Family of Companies | Boosting Long-Term Survival Rates with a Single Injection: How This Innovative Drug Developer Is Taking on Leukemia
CAR-T cell therapy is seen as a new hope in humanity's fight against cancer.
Chip companies, surgical robots, and consumer tech brands close new funding rounds | Rongbao · June
Notable developments to watch in June.
February: Returning to Our Imagination of the World | 5Y News Monthly
The big news from last month.
FreeS Report 23: Crossing the "Valley of Death": Systemic New Opportunities in Small-Molecule Drug R&D
Across every stage of preclinical drug R&D, new infrastructure, methods, and tools are emerging in China — making rapid, low-cost experimentation possible.
5Y News｜Vivace Therapeutics Announces Completion of Angel Round Raising Tens of Millions of RMB
Huanyi Bio announced the completion of an angel funding round of tens of millions of RMB, led by 5Y Capital.
FreeS Fund Report 16: The Truth About Early-Stage Healthcare Investing and China Speed | Frees Fund
Is early-stage healthcare investment really as "high-cost, high-risk, slow-return" as they say?
FreeS Fund Report 15: The Life Gamble — The Risk-Filled Journey of Drug R&D | Frees Fund
The Ideals and Persistence Behind a 3% Success Rate.
